Table 4.

Clinical profile, treatment and outcome of 14 patients with positive MZN staining of their cerebrospinal fluid classified as “not TBM”.

Gender	Age (years)	Outcome	Final diagnosis	TBM score*	TBM treatment**	Other antibiotics
M	30	Good	Cryptococcal meningitis	9	Y	ceftriaxone, fluconazole
M	7	Good	Cryptococcal meningitis	10	N	ceftriaxone, meropenem, fluconazole
F	49	Good	Meningeoma	9	N	–
M	68	Good	Cryptococcal meningitis	15	Y	fluconazole
F	17	Good	Bacterial meningitis	11	N	ceftriaxone, meropenem, vancomycin
M	54	Good	Bacterial meningitis	9	N	ceftriaxone
M	61	Good	Bacterial meningitis	10	N	ceftriaxone, vancomycin
M	25	Good	Bacterial meningitis	10	N	ceftriaxone
M	5	Good	Acute lymphoblastic leukemia	7	N	ceftriaxone
F	11	Good	Bacterial meningitis	8	N	ceftriaxone
M	39	Good	Cryptococcal meningitis	9	Y	ceftriaxone, fluconazole
M	18	Good	Cryptococcal meningitis	8	Y	ceftriaxone, fluconazole
M	43	Dead	Cryptococcal meningitis	9	N	fluconazole
M	33	Good	Bacterial meningitis	10	N	ceftriaxone, meropenem, ciprofloxacin

MZN, Modified Ziehl-Neelsen; TBM, tuberculous meningitis; M, Male; F, Female; Y, yes; N, no;

^*Score according to the consensus uniform research case definition criteria (Marais et al., 2010);

^**Isoniazid, Rifampicin, Pyrazinamide, and Ethambutol; All patients were HIV-uninfected.